Cardiovascular risk stratification in type 1 diabetes mellitus (T1DM) remains complex, particularly in the presence of metabolic syndrome (MS) and diabetic kidney disease. A cohort analysis published in the Journal of Diabetes and Its Complications evaluated the interplay between chronic low-grade inflammation, assessed by high-sensitivity C-reactive protein (hs-CRP), and MS in determining coronary artery disease (CAD) risk across different stages of kidney involvement.

The study included 4014 participants with T1DM from the Finnish Diabetic Nephropathy Study. Hs-CRP levels were dichotomized based on kidney disease group medians, and participants were categorized by MS and hs-CRP status. CAD outcomes were identified through hospital discharge registries and death certificates during follow-up.

Hs-CRP levels increased progressively with the number of MS components, irrespective of kidney disease severity (p<0.001). In individuals with normal kidney function, CAD risk was higher in those with combined MS and elevated hs-CRP (adjusted hazard ratio [HR] 1.53; 95% confidence interval [CI], 1.06 to 2.21), while isolated MS or hs-CRP elevation showed smaller, non-significant differences. In participants with albuminuria and preserved eGFR, no increased CAD risk was observed across MS or hs-CRP categories. In contrast, among those with albuminuria and reduced eGFR, increased CAD risk was observed in the MS+/hs-CRP− group (HR 2.00; 95% CI, 1.06 to 3.77).

These findings indicate that hs-CRP levels vary with metabolic syndrome burden and may refine CAD risk stratification in type 1 diabetes, with differential associations observed across stages of kidney disease.